Solid dosage form
AssigneeIx Biopharma Pte Ltd
InventorsChin Beng Stephen LIM, Vivian Bruce SUNDERLAND, Yip Hang Eddy LEE
Life of this patent
Estimating the term…
Abstract
There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.
Claims27
A solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises:
- a) at least one biologically active material, and
- b) at least one matrix forming agent,
- wherein the dosage form substantially dissolves in the oral cavity and wherein the biologically active material is chosen from the list comprising:
- at least one cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor, an active material that binds to one or more adrenergic receptors, and an N-methyl-D-aspartate receptor antagonist.
A method to produce a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form substantially dissolves in the oral cavity, comprising the steps of:
- a) combining at least one matrix forming agent with a biologically active material to form a homogeneous mixture;
- and
- b) freeze drying the mixture to prepare the solid dosage form of the present invention
- wherein the biologically active material is chosen from the list comprising:
- at least one cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor, an active material that binds to one or more adrenergic receptors, and an N-methyl-D-aspartate receptor antagonist.
A kit comprising:
- a) a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form substantially dissolves in the oral cavity, wherein the dosage form comprises:
- (i) at least one biologically active material, and
- (ii) at least one matrix forming agent;
- and
- b) instructions for use
- wherein the biologically active material is chosen from the list comprising:
- at least one cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor, an active material that binds to one or more adrenergic receptors, and an N-methyl-D-aspartate receptor antagonist.
A solid dosage form wafer adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises:
- a) at least one biologically active material, and
- b) at least one matrix forming agent,
- wherein the wafer substantially dissolves in the oral cavity and wherein the biologically active material is chosen from the list comprising:
- at least one cyclic guanosine monophosphate (cGMP) phosphodiesterase type 5 (PDE5) inhibitor, an active material that binds to one or more adrenergic receptors, and an N-methyl-D-aspartate receptor antagonist.
Dependencies are inferred from the claim text.